The expanding role of pertuzumab in the treatment of HER2-positive breast cancer

Breast cancer tumors that demonstrate gene amplification or overexpression of human epidermal growth factor receptor 2 (HER2) are classified as HER2-positive. They account for approximately 15% of all breast cancers and represent an adverse prognostic factor. Over the past years, many new therapies...

Descripción completa

Detalles Bibliográficos
Autores principales: Moya-Horno, I, Cortés, J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445592/
https://www.ncbi.nlm.nih.gov/pubmed/26056489
http://dx.doi.org/10.2147/BCTT.S61579

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445592/
https://www.ncbi.nlm.nih.gov/pubmed/26056489
http://dx.doi.org/10.2147/BCTT.S61579

Ejemplares similares